Porth's Essentials of Pathophysiology, 4e

1138

Musculoskeletal Function

U N I T 1 2

10. Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 2006;194:S3–S11. 11. Rosen CJ. Postmenopausal osteoporosis. N Engl J Med. 2005;353:595–603. 12. Lambert JK, Zaidi M, Mechanick JI. Male osteoporosis: epidemiology and the pathogenesis of aging bones. Curr Osteoporos Rep. 2011;11(9):229–236. 13. Gennari L, Bilezikian JP. Osteoporosis in men. Endocrinol Metab Clin North Am. 2007;36:399–419. 14. Hudec SM, Camacho PM. Secondary osteoporosis. Endocr Pract. 2013;19(1):120–128. 15. Russell LA. Osteoporosis and osteomalacia. Rheum Dis Clin North Am. 2010;36:665–680. 16. Maricic M. Update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am. 2011;37:415–431. 17. Rothman MS, Bessesen TB. HIV infection and osteoporosis: pathophysiology, diagnosis, and treatment options. Curr Osteoporos Rep. 2012;10(4):270–277. 18. Shaw NJ. Management of osteoporosis in children. Eur J Endocrinol. 2008;159:S33–S39. 19. Beals KA, Meyer NL. Female athlete triad update. Clin Sports Med. 2007;26:69–80. 20. Sweet MG, Sweet JM, Jeremiah MP, et al. Diagnosis and treatment of osteoporosis. Am Fam Physician. 2009;79(3):193–202. 21. Warriner AH, Saag KG. Osteoporosis diagnosis and medical treatment. Orthop Clin North Am. 2013;44(2): 125–135. 22. National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis . Washington, DC: National Osteoporosis Foundation; 2008. 23. U.S. Preventive Services Task Force. Screening for osteoporosis. Available at: http://www.uspreventiveservicestaskforce.org/ uspstf10/osteoporosis/osteors.htm. Accessed September 29, 2013. 24. Katzung BG, Masters SB, Trevor AJ. Basic & Clinical Pharmacology . 12th ed. New York, NY: McGraw-Hill Lange; 2013:782–783. 25. Cauley JA, Robbins J, Chen Z, et al., for the Women’s Health Initiative. Effects of estrogen plus progestin on risk of fracture and bone mineral density. JAMA. 2003;290:1729–1738. 26. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–281. 27. Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr. 2008;87(suppl):1080D–1086D. 28. Berg EE. Rickets. Orthop Nurs. 2004;23(1):53–55. 29. Nield LS, Mahajan P, Joshi A, et al. Rickets: not a disease of the past. Am Fam Physician. 2006;74:619–630. 30. Mughal MP. Rickets. Curr Osteoporos Rep. 2011;9:291–299. 31. Misra M, Pacaud D, Petryk A, et al. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics. 2008;122:398–417. 32. Ralston SH. Paget’s disease of bone. N Engl J Med. 2013;368(7):644–650. 33. Roodman GD, Windle JJ. Paget disease of bone. J Clin Invest. 2005;115:200–208. 34. Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011;63(3):633–639. 35. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–2219. 36. Pedersen M, Jacobsen S, Garred P, et al. Strong combined gene-environment effects in anti-cyclic citrullinated peptide- positive rheumatoid arthritis: a nationwide case-control study in Denmark. Arthritis Rheum. 2007;56(5):1446–1453.

37. Sweeny SE, Harris ED, Firestein GS. Clinical features of rheumatoid arthritis. In: Firestein GS, Budd RC, Gabriel SE, et al., eds. Kelley’s Textbook of Rheumatology . 9th ed. Philadelphia, PA: Elsevier Saunders; 2012:1108–1136. 38. Wasserman AM. Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2011;84(11):1245–1282. 39. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569. 40. Oliver AM, St. Clair EW. Rheumatoid arthritis: treatment and assessment. In: Klippel JH, Stone JH, Crofford LJ, et al., eds. Primer on the Rheumatic Diseases . 13th ed. New York, NY: Springer; 2008:133–141. 41. Singh, JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying anti-rheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64(5):625–639. 42. Pietsky DS. Systemic lupus erythematosus: epidemiology, pathology, and pathogenesis. In: Klippel JR, Stone JH, Crofford LJ, et al., eds. Primer on the Rheumatic Diseases . 13th ed. New York, NY: Springer; 2008:303–313. 43. Kumar V, Abbas AK, Fausto N, et al. Robbins and Cotran Pathologic Basis of Disease . 8th ed. Philadelphia, PA: Saunders Elsevier; 2010:213–226. 44. Schur P, Hahn B. Epidemiology and pathogenesis of systemic lupus erythematosus. January 2014. Available at: http://www. uptodate.com/contents/epidemiology-and-pathogenesis-of- systemic-lupus-erythematosus#H443498. Accessed February 21, 2014. 45. Dall’era M, Wofsy D. Clinical features of systemic lupus erythematosus. In: Firestein GS, Budd RC, Gabriel SE, et al., eds. Kelley’s Textbook of Rheumatology . 9th ed. Philadelphia, PA: Elsevier Saunders; 2012:1283–1301. 46. Manzi S, Kao AH. Systemic lupus erythematosus: treatment and assessment. In: Klippel JR, Stone JH, Crofford LJ, et al., eds. Primer on the Rheumatic Diseases . 13th ed. New York, NY: Springer; 2008:303–313. 47. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009; 360:1989–2008. 48. Boin F, Wigley FM. Clinical features and treatment of scleroderma. In: Firestein GS, Budd RC, Gabriel SE, et al., eds. Kelley’s Textbook of Rheumatology . 9th ed. Philadelphia, PA: Elsevier Saunders; 2012:1366–1395. 49. Hinchcliff M, Varga J. Systemic sclerosis/scleroderma: a treatable multisystem disease. Am Fam Physician. 2008;78(8):961–969. 50. Buch MH, Seibold JR. Systemic sclerosis: treatment and assessment. In: Klippel JR, Stone JH, Crofford LJ, et al., eds. Primer on the Rheumatic Diseases . 13th ed. New York, NY: Springer; 2008:359–362. 51. Dougodos M, Baeten D. Spondyloarthritis. Lancet. 2011;377:2127–2137. 52. Rosenbaum, JT, Davey, MP. Time for a gut check: evidence for the hypotheses that HLA-B27 predisposes to ankylosing spondylitis by altering the microbiome. Arthritis Rheum. 2011;63(11):3195–3198. 53. Elyan M, Khan MA. Diagnosing ankylosing spondylitis. J Rheumatol Suppl. 2006;33(78):12–23. 54. Clegg DO. Treatment of ankylosing spondylitis. J Rheumatol Suppl. 2006;33(78):24–31. 55. Carter JD, Hudson AP. Reactive arthritis: clinical aspects and medical management. Rheum Dis Clin North Am. 2009;35:21–44. 56. Fitzgerald O. Psoriatic arthritis. In: Firestein GS, Budd RC, Gabriel SE, et al., eds. Kelley’s Textbook of Rheumatology . 9th ed. Philadelphia, PA: Elsevier Saunders; 2012:1232–1249.